KR101699145B1 - 페닐알킬설파메이트 화합물 및 이를 포함하는 근육 이완제 조성물 - Google Patents

페닐알킬설파메이트 화합물 및 이를 포함하는 근육 이완제 조성물 Download PDF

Info

Publication number
KR101699145B1
KR101699145B1 KR1020147035195A KR20147035195A KR101699145B1 KR 101699145 B1 KR101699145 B1 KR 101699145B1 KR 1020147035195 A KR1020147035195 A KR 1020147035195A KR 20147035195 A KR20147035195 A KR 20147035195A KR 101699145 B1 KR101699145 B1 KR 101699145B1
Authority
KR
South Korea
Prior art keywords
methyl
preparation
dioxolan
dioxaspiro
sulfamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035195A
Other languages
English (en)
Korean (ko)
Other versions
KR20150023393A (ko
Inventor
용문 최
Original Assignee
(주)바이오팜솔루션즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)바이오팜솔루션즈 filed Critical (주)바이오팜솔루션즈
Publication of KR20150023393A publication Critical patent/KR20150023393A/ko
Application granted granted Critical
Publication of KR101699145B1 publication Critical patent/KR101699145B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147035195A 2012-06-15 2013-06-14 페닐알킬설파메이트 화합물 및 이를 포함하는 근육 이완제 조성물 Active KR101699145B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660064P 2012-06-15 2012-06-15
US61/660,064 2012-06-15
PCT/KR2013/005279 WO2013187727A1 (en) 2012-06-15 2013-06-14 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same

Publications (2)

Publication Number Publication Date
KR20150023393A KR20150023393A (ko) 2015-03-05
KR101699145B1 true KR101699145B1 (ko) 2017-02-03

Family

ID=49758484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035195A Active KR101699145B1 (ko) 2012-06-15 2013-06-14 페닐알킬설파메이트 화합물 및 이를 포함하는 근육 이완제 조성물

Country Status (9)

Country Link
US (1) US9221783B2 (enExample)
EP (1) EP2861571B1 (enExample)
JP (1) JP6001168B2 (enExample)
KR (1) KR101699145B1 (enExample)
CN (1) CN104428292B (enExample)
BR (1) BR112014031396B1 (enExample)
CA (1) CA2874988C (enExample)
ES (1) ES2635067T3 (enExample)
WO (1) WO2013187727A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088272A1 (en) 2013-12-12 2015-06-18 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating pain
US9937145B2 (en) * 2013-12-12 2018-04-10 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compound for use in preventing or treating epilepsy
ES2704928T3 (es) 2013-12-12 2019-03-20 Bio Pharm Solutions Co Ltd Compuestos derivados de sulfamato para su uso en el tratamiento o alivio del dolor
US11896593B2 (en) * 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
WO2007005935A2 (en) 2005-07-06 2007-01-11 Molecular Neuroimaging, Llc Norepinephrine transporter radiotracers and methods of syntheses thereof
JP2009513646A (ja) 2005-10-25 2009-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ α‐ガラクトシルセラミドのアナログ及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459160A (en) * 1891-09-08 Half to isaac l
US2884444A (en) 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US2937119A (en) 1959-06-11 1960-05-17 Carter Prod Inc Nu-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamates
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265727A (en) 1962-06-26 1966-08-09 Armour Pharma Phenyl alkyl-1, 2 dicarbamates
US4591601A (en) 1985-04-12 1986-05-27 Mcneilab, Inc. Anticonvulsant dioxolane methane sulfamates
US4792569A (en) 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5025031A (en) 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
JPH05140144A (ja) * 1991-11-14 1993-06-08 Nitto Denko Corp 新規なアルコール及びその製法、及び新規なエステル並びにこの新規なアルコールからニンジン類の発根誘起物質を製造する方法
JPH07228549A (ja) * 1994-02-17 1995-08-29 Japan Tobacco Inc 新規な4−アリール−2,3−ジヒドロキシ酪酸誘導体及びその製造方法
JP4145492B2 (ja) * 1998-09-23 2008-09-03 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング テトラヒドロピリドエーテル
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
WO2007005935A2 (en) 2005-07-06 2007-01-11 Molecular Neuroimaging, Llc Norepinephrine transporter radiotracers and methods of syntheses thereof
JP2009513646A (ja) 2005-10-25 2009-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ α‐ガラクトシルセラミドのアナログ及びその使用

Also Published As

Publication number Publication date
EP2861571A1 (en) 2015-04-22
EP2861571A4 (en) 2015-11-04
BR112014031396B1 (pt) 2019-11-26
BR112014031396A2 (pt) 2017-06-27
EP2861571B1 (en) 2017-05-03
CN104428292B (zh) 2017-02-08
CA2874988C (en) 2016-05-24
JP2015531746A (ja) 2015-11-05
CN104428292A (zh) 2015-03-18
JP6001168B2 (ja) 2016-10-05
KR20150023393A (ko) 2015-03-05
US20150266848A1 (en) 2015-09-24
US9221783B2 (en) 2015-12-29
ES2635067T3 (es) 2017-10-02
WO2013187727A1 (en) 2013-12-19
CA2874988A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
ES2710902T3 (es) Compuesto derivado de carbamatos de fenilalquilo y composición farmacéutica que contiene el mismo
JP7013245B2 (ja) トレプロスチニル誘導体ならびにその組成物および使用
KR101725696B1 (ko) 신규한 이환형 피리딘온
KR101699145B1 (ko) 페닐알킬설파메이트 화합물 및 이를 포함하는 근육 이완제 조성물
KR20160045797A (ko) 리소포스파티드산 수용체 길항제로서의 아미드 유도체
ES2711619T3 (es) Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
KR101792999B1 (ko) 간질 예방 또는 치료용 설파메이트 유도체 화합물
JP6220975B2 (ja) 痛症を治療又は緩和するためのスルファメート誘導体化合物。{sulfamate derivative compounds for use in treating or alleviating pain}
JP7648746B2 (ja) 精神疾患の治療又は軽減のためのスルファメート誘導体化合物
CN1268938A (zh) 氨基环烷烃化合物
TW201031624A (en) Biaryl benzylamine derivatives
TW202241845A (zh) 經取代的環己烷甲醯胺、其製備方法及其治療用途
Soltanzadeh Highly Stereoselective Intermolecular Halofunctionalization of Olefins

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20141215

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160607

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20161228

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170117

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170117

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20191126

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20191126

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20201216

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20211228

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20221226

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240110

Start annual number: 8

End annual number: 8